BiotechTube
Home/Pipeline/Vaxine Flu Vaccine

Vaxine Flu Vaccine

Seasonal Influenza

Phase 2/3Active

Key Facts

Indication
Seasonal Influenza
Phase
Phase 2/3
Status
Active
Company
Vaxine

About Vaxine

AI‑enhanced vaccine developer using the Advax™ adjuvant platform for infectious disease and immunotherapy.

View full company profile

Therapeutic Areas

Infectious DiseaseOncologyAllergyNeurology

Other Seasonal Influenza Drugs

DrugCompanyPhase
Nasovac‑S™BioDiemCommercial
DeFluvacBioDiemCommercial
MF59-Adjuvanted Seasonal VaccinesCSL SeqirusMarketed
Flucelvax Quadrivalent (cell-based)CSL SeqirusMarketed
Flublok Quadrivalent (recombinant)CSL SeqirusMarketed
Aramis FluVacAramis BiotechnologiesPreclinical
mRNA-based Influenza VaccineSanofiPhase 3
mRNA-1010/1011ModernaPhase 3
Standalone Seasonal Influenza VaccineNovavaxPhase 3
AdFlu‑QAdimmunePreclinical
LUNAR®-FLU (ARCT-2138)Arcturus TherapeuticsPhase 1
Oral Influenza VaccineVaxartPhase 2